| abstract |
The present invention provides a bioactive compound that can be reacted with a polymer such as albumin to form a covalent complex, and the resulting complex exhibits the desired biological activity in vivo. More particularly, these complexes are isolated complexes comprising a bioactive moiety covalently bound to a bridging group and a protein. These complexes are made by conjugating a biologically active moiety, such as a renin inhibitor or viral fusion inhibitor peptide, with a purified and isolated protein. These complexes have a longer lifespan in the bloodstream than unconjugated molecules, and exhibit biological activity for a longer time than unconjugated molecules. The present invention also provides antiviral compounds that are inhibitors of viral infection and / or exhibit anti-fusion properties. In particular, the invention relates to viruses such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV). And a long-acting compound for the treatment of viral infection. |